Lucentis - a new macular degeneration treatment

Novartis has launched Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration.

is a humanised recombinant monoclonal antibody fragment that targets human vascular endothelial growth factor A (VEGF-A). Ranibizumab prevents binding of VEGF-A to its receptors which leads to endothelial cell proliferation and neovascularisation, as well as vascular leakage, all of which are thought to contribute to the progression of the neovascular form of age-related macular degeneration.

Further information: Novartis 01276 692255

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

Excessive steroid dosing highlighted in inflammatory bowel disease

Excessive steroid dosing highlighted in inflammatory bowel disease

Some patients with Crohn's disease or ulcerative colitis...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Femoston 1/10, Flixotide Nebules, Synalar C...

Blood Glucose Testing Strips and Meters

Blood Glucose Testing Strips and Meters

Compatible test strips for blood glucose meters.

intelog Learning's Espresso CPD helps GPs to top up credits for appraisal

intelog Learning's Espresso CPD helps GPs to top up credits for appraisal

Bite-size Espresso learning can help you top up your...